<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlm.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Cancer</journal-id><journal-title>Molecular Cancer</journal-title><issn pub-type="epub">1476-4598</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1476-4598-8-86</article-id><article-id pub-id-type="pmid">19835597</article-id><article-id pub-id-type="doi">10.1186/1476-4598-8-86</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Hypomethylation and expression of <italic>BEX2, IGSF4 </italic>and <italic>TIMP3 </italic>indicative of <italic>MLL </italic>translocations in Acute Myeloid Leukemia</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>R&#x000f6;hrs</surname><given-names>Sonja</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>sro07@dsmz.de</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Dirks</surname><given-names>Wilhelm G</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>wdi@dsmz.de</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Meyer</surname><given-names>Claus</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>claus.meyer@em.uni-frankfurt.de</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Marschalek</surname><given-names>Rolf</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>rolf.marschalek@em.uni-frankfurt.de</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Scherr</surname><given-names>Michaela</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>M.Scherr@t-online.de</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Slany</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>rslany@biologie.uni-erlangen.de</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Wallace</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>AndrewW@CMMC.nhs.uk</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Drexler</surname><given-names>Hans G</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>hdr@dsmz.de</email></contrib><contrib id="A9" corresp="yes" contrib-type="author"><name><surname>Quentmeier</surname><given-names>Hilmar</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>hqu@dsmz.de</email></contrib></contrib-group><aff id="I1"><label>1</label>DSMZ-German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany</aff><aff id="I2"><label>2</label>Institute of Pharmaceutical Biology/Diagnostic Centre of Acute Leukaemia, Goethe University, Frankfurt, Germany</aff><aff id="I3"><label>3</label>Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Medical School Hannover, Hannover, Germany</aff><aff id="I4"><label>4</label>Department of Genetics, Friedrich-Alexander University, Erlangen, Germany</aff><aff id="I5"><label>5</label>Department of Medical Genetics, St Mary's Hospital, Manchester, UK</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>16</day><month>10</month><year>2009</year></pub-date><volume>8</volume><fpage>86</fpage><lpage>86</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molecular-cancer.com/content/8/1/86"/><history><date date-type="received"><day>3</day><month>6</month><year>2009</year></date><date date-type="accepted"><day>16</day><month>10</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 R&#x000f6;hrs et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>R&#x000f6;hrs et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> R&#x000f6;hrs Sonja sro07@dsmz.de </dc:author><dc:title> Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in Acute Myeloid Leukemia </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>Molecular Cancer 8(1): 86-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1476-4598(2009)8:1&#x0003c;86&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1476-4598</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Translocations of the <italic>Mixed Lineage Leukemia </italic>(<italic>MLL</italic>) gene occur in a subset (5%) of acute myeloid leukemias (AML), and in mixed phenotype acute leukemias in infancy - a disease with extremely poor prognosis. Animal model systems show that <italic>MLL </italic>gain of function mutations may contribute to leukemogenesis. Wild-type (wt) <italic>MLL </italic>possesses histone methyltransferase activity and functions at the level of chromatin organization by affecting the expression of specific target genes. While numerous MLL fusion proteins exert a diverse array of functions, they ultimately serve to induce transcription of specific genes. Hence, acute lymphoblastic leukemias (ALL) with <italic>MLL </italic>mutations (<italic>MLL</italic>mu) exhibit characteristic gene expression profiles including high-level expression of <italic>HOXA </italic>cluster genes. Here, we aimed to relate <italic>MLL </italic>mutational status and tumor suppressor gene (TSG) methylation/expression in acute leukemia cell lines.</p></sec><sec><title>Results</title><p>Using MS-MLPA (methylation-specific multiplex ligation-dependent probe amplification assay), methylation of 24 different TSG was analyzed in 28 <italic>MLL</italic>mu and <italic>MLL</italic>wt acute leukemia cell lines. On average, 1.8/24 TSG were methylated in <italic>MLL</italic>mu AML cells, while 6.2/24 TSG were methylated in <italic>MLL</italic>wt AML cells. Hypomethylation and expression of the TSG <italic>BEX2, IGSF4 </italic>and <italic>TIMP3 </italic>turned out to be characteristic of <italic>MLL</italic>mu AML cell lines. <italic>MLL</italic>wt AML cell lines displayed hypermethylated TSG promoters resulting in transcriptional silencing. Demethylating agents and inhibitors of histone deacetylases restored expression of <italic>BEX2, IGSF4 </italic>and <italic>TIMP3</italic>, confirming epigenetic silencing of these genes in <italic>MLL</italic>wt cells. The positive correlation between <italic>MLL </italic>translocation, TSG hypomethylation and expression suggested that <italic>MLL </italic>fusion proteins were responsible for dysregulation of TSG expression in <italic>MLL</italic>mu cells. This concept was supported by our observation that <italic>Bex2 </italic>mRNA levels in <italic>MLL-ENL </italic>transgenic mouse cell lines required expression of the <italic>MLL </italic>fusion gene.</p></sec><sec><title>Conclusion</title><p>These results suggest that the conspicuous expression of the TSG <italic>BEX2, IGSF4 </italic>and <italic>TIMP3 </italic>in <italic>MLL</italic>mu AML cell lines is the consequence of altered epigenetic properties of <italic>MLL </italic>fusion proteins.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Translocations of the <italic>Mixed Lineage Leukemia </italic>(<italic>MLL</italic>) gene occur in a subset of acute leukemias. The correlation between <italic>MLL </italic>translocations and expression of specific gene clusters is so evident that "mixed lineage leukemia", originally applied to biphenotypic acute leukemia cells, is now used to describe the <italic>MLL </italic>mutant (<italic>MLL</italic>mu) acute leukemias [<xref ref-type="bibr" rid="B1">1</xref>]. High expression levels of a set of <italic>HOXA </italic>cluster genes are characteristic of <italic>MLL </italic>mutations in primary acute lymphoblastic leukemia (ALL) cells, and in <italic>MLL</italic>mu ALL cell lines [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. For acute myeloid leukemia (AML) cell lines, a similar correlation exists between <italic>MLL </italic>translocations and expression of the gene <italic>brain expressed X-linked 2 </italic>(<italic>BEX2</italic>, formerly called <italic>BEX1</italic>) [<xref ref-type="bibr" rid="B3">3</xref>]. In healthy people, <italic>BEX2 </italic>is expressed in the brain and, more weakly, in pancreas and testis, but not in hematopoetic cells [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. In leukemia cell lines, we found <italic>BEX2 </italic>expression to be restricted to <italic>MLL</italic>mu AML. <italic>MLL </italic>wild-type (<italic>MLL</italic>wt) AML and ALL cell lines and, notably, also <italic>MLL</italic>mu ALL cell lines do not transcribe this gene, suggesting that <italic>BEX2 </italic>expression might be a diagnostic marker for <italic>MLL</italic>mu AML [<xref ref-type="bibr" rid="B3">3</xref>].</p><p>Several lines of evidence indicate that epigenetic mechanisms are responsible for the regulation of <italic>BEX2 </italic>expression: (i) the <italic>BEX2 </italic>promoter is methylated in <italic>MLL</italic>wt and unmethylated in <italic>MLL</italic>mu AML cell lines, thus demonstrating an inverse correlation between gene expression and promoter methylation [<xref ref-type="bibr" rid="B5">5</xref>]; (ii) demethylating agents and inhibitors of histone deacetylases (HDAC) induce <italic>BEX2 </italic>expression in <italic>MLL</italic>wt cells [<xref ref-type="bibr" rid="B5">5</xref>]; (iii) chromatin immunoprecipitation experiments show that histone acetylation plays a role in <italic>BEX2 </italic>regulation: immunoprecipitation of acetylated histone H3 coprecipitates chromatin from the 5' region of <italic>BEX2 </italic>in <italic>MLL</italic>mu, but not in <italic>MLL</italic>wt cells [<xref ref-type="bibr" rid="B5">5</xref>].</p><p><italic>BEX1 </italic>and <italic>BEX2 </italic>have recently been described as epigenetically controlled candidate tumor suppressor genes (TSG) in malignant glioma [<xref ref-type="bibr" rid="B6">6</xref>]. Promoter hypermethylation of TSG is often seen in malignant diseases and, according to a widely held view, contributes to the rise of malignant cell clones by restraining tumor suppressor gene expression [<xref ref-type="bibr" rid="B7">7</xref>]. Moreover, unique profiles of hypermethylated CpG islands have been described which are characteristic of different neoplasias [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>].</p><p>We applied a multiplex methylation detection assay to find out whether the connection between the <italic>MLL </italic>mutational status and promoter methylation is unique to <italic>BEX2 </italic>or if this correlation applies to other TSG as well. Results show that <italic>MLL</italic>wt AML cell lines exhibit a higher propensity for TSG promoter hypermethylation than <italic>MLL</italic>mu cell lines. This is especially true for <italic>Immunoglobulin superfamily member 4 </italic>(<italic>IGSF4/CADM1), Retinoic acid receptor beta (RARB) </italic>and <italic>Tissue inhibitor of matrix metalloproteinase 3 </italic>(<italic>TIMP3</italic>), all with <italic>MLL</italic>-dependent methylation profiles resembling <italic>BEX2</italic>. According to methylation-specific PCR (MSP), primary AML cells without rearrangement of the <italic>MLL </italic>gene also show a preference for TSG hypermethylation.</p><p>Our experimental results suggest that MLLmu proteins enhance the expression of distinct TSG and that this might be the consequence of altered epigenetic regulatory mechanisms of the fusion proteins.</p></sec><sec><title>Results and Discussion</title><sec><title>Methylation patterns of TSG differ in <italic>MLL</italic>mu and <italic>MLL</italic>wt cell lines</title><p>Hypermethylation of CpG islands in the promoter regions of TSG occurs widely in malignancy, resulting in transcriptional inactivation which promotes cancerogenesis [<xref ref-type="bibr" rid="B7">7</xref>]. Unique profiles of hypermethylated CpG islands have been described, being characteristic of different neoplasias [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. <italic>BEX2 </italic>is a newly described TSG, which is silenced by hypermethylation in malignant glioma [<xref ref-type="bibr" rid="B6">6</xref>]. With leukemia/lymphoma cell lines as model systems, we have shown that <italic>BEX2 </italic>hypomethylation and gene expression typifies <italic>MLL</italic>mu AML [<xref ref-type="bibr" rid="B3">3</xref>]. <italic>BEX2 </italic>silencing in <italic>MLL</italic>wt cells is the result of epigenetic mechanisms like promoter methylation and histone deacetylation [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. Here, we set out to elucidate whether the described correlation between promoter hypomethylation and genetically rearranged <italic>MLL </italic>is peculiar to <italic>BEX2</italic>, or whether other TSG display similar features.</p><p>Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) was performed to assess the methylation status of 24 TSG in 28 acute leukemia cell lines, 50% with <italic>MLL </italic>translocations (see Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). ALL-derived cell lines showed a higher percentage of methylated TSG than AML cell lines (Fig. <xref ref-type="fig" rid="F1">1</xref>). The mean number of methylated TSG in ALL cell lines was independent of <italic>MLL </italic>mutational status (Fig. <xref ref-type="fig" rid="F1">1</xref>). In contrast, 25% of all TSG analyzed were methylated in <italic>MLL</italic>wt, but only 7% in <italic>MLL</italic>mu AML cell lines (Fig. <xref ref-type="fig" rid="F1">1</xref>). Provided that the TSG tested are representative, <italic>MLL</italic>mu AML cell lines display a significantly lower tendency to TSG hypermethylation than <italic>MLL</italic>wt cell lines.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Low tendency for TSG methylation in <italic>MLL </italic>mu AML cell lines</bold>. Methylation status of 24 TSG was determined by MS-MLPA (see also: Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). Mean numbers of methylated TSG and standard deviations in the different groups of leukemia cell lines are shown. Note that <italic>MLL</italic>mu AML, but not <italic>MLL</italic>mu ALL cell lines show reduced TSG methylation.</p></caption><graphic xlink:href="1476-4598-8-86-1"/></fig></sec><sec><title>Methylation status of <italic>BEX2, IGSF4, RARB </italic>and <italic>TIMP3 </italic>is indicative of <italic>MLL</italic>mu AML</title><p>Expression array analysis allows classification of tumors, including the discrimination of acute leukemias with/without <italic>MLL </italic>translocations [<xref ref-type="bibr" rid="B1">1</xref>]. Likewise, profiles of promoter hypermethylation are unique for different types of cancer and have also been used to identify lymphomatous entities [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B12">12</xref>]. We evaluated our MS-MLPA data to find out whether <italic>MLL</italic>mu and <italic>MLL</italic>wt cell lines could be distinguished via their respective TSG methylation patterns (see Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). In addition to the 24 TSG included in this assay, we tested methylation of <italic>BEX2 </italic>by a methylation-sensitive DNA restriction- and quantitative real-time PCR-assay.</p><p>Promoter methylation of TSG <italic>BEX2</italic>, <italic>IGSF4</italic>, <italic>RARB </italic>and <italic>TIMP3 </italic>distinguished <italic>MLL</italic>mu and <italic>MLL</italic>wt AML: 0/7 <italic>MLL</italic>mu and 6/7 <italic>MLL</italic>wt AML cell lines exhibited methylation of at least two of these four TSG (p-value = 0.002, Fisher's exact test) (Fig. <xref ref-type="fig" rid="F2">2</xref>). Neither these four genes nor any other set of TSG analyzed distinguished between <italic>MLL</italic>mu and <italic>MLL</italic>wt ALL cell lines, suggesting that a myeloid gene expression background was obligatory for the <italic>MLL</italic>-specific methylation pattern (see Fig. <xref ref-type="fig" rid="F2">2</xref>, Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>TSG methylation predictive for classification of acute leukemia cell lines</bold>. Methylation was assessed by MS-MLPA (see also Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>) or by DNA digestion with methylation-sensitive <italic>Hha</italic>I plus promoter-specific quantitative real-time PCR (for analysis of <italic>BEX2</italic>). Green: methylation level &#x02265; 10%; yellow: methylation level &#x0003c; 10%. <italic>BEX2, IGSF4, RARB </italic>and <italic>TIMP3 </italic>are methylated in ALL and in <italic>MLL</italic>wt AML, but not in <italic>MLL</italic>mu AML. This correlation is statistically significant with p-values &#x0003c; 0.05 for <italic>BEX2</italic>, <italic>RARB </italic>and <italic>TIMP3 </italic>and with a p-value of 0.051 for <italic>IGSF4 </italic>(Fisher's exact test). Methylation analysis of <italic>DAPK1, FHIT </italic>and <italic>TP73 </italic>discriminates between ALL and AML cell lines (p-values &#x02264; 0.01, Fisher's exact test). Other TSG (e.g. <italic>BRCA2 </italic>and <italic>ESR1</italic>) are methylated or unmethylated in the majority of cell lines with no preference for subtype.</p></caption><graphic xlink:href="1476-4598-8-86-2"/></fig><p>Most of the 24 TSG analyzed did not allow the histological origin of the cells to be inferred, being either methylated (e.g. <italic>ESR1</italic>) or unmethylated (e.g. <italic>BRCA2</italic>) in the majority of cell lines (see Fig. <xref ref-type="fig" rid="F2">2</xref>, Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). Furthermore, deletions, notably those of the TSG <italic>CDKN2A </italic>and <italic>CDKN2B</italic>, occurred in ALL as well as in AML cell lines (see Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). However, the methylation pattern of three genes (<italic>DAPK1</italic>, <italic>FHIT</italic>, <italic>TP73</italic>) was highly characteristic (p-values = 0.01, Fisher's exact test) of either ALL or AML (Fig. <xref ref-type="fig" rid="F2">2</xref>). These results show that analysis of TSG methylation may also be used to recognize distinct leukemic entities. Noteworthy in the context of our study, methylation patterns of <italic>BEX2, IGSF4, RARB </italic>and <italic>TIMP3 </italic>allowed discrimination between <italic>MLL</italic>mu and wt AML cell lines (Fig. <xref ref-type="fig" rid="F2">2</xref>).</p><p>MS-MLPA is a screening technique and obtained results rely on the analysis of one single CpG-site in the promoter region. To verify the validity of the methylation status as determined by MS-MLPA or <italic>HhaI</italic>-restriction-sensitive PCR assay (for <italic>BEX2</italic>), we performed MSP after bisulfite conversion of DNA for <italic>BEX2, IGSF4 and TIMP3 </italic>(see Additional file <xref ref-type="supplementary-material" rid="S2">2</xref>). The respective CpGs tested by MSP and MS-MLPA were located at different promoter sites. The accuracy of MS-MLPA/<italic>Hha</italic>I-restriction-sensitive PCR to predict the methylation status of these three TSG as determined by MSP was reassuringly high (83%), supporting the validity of MS-MLPA for use in our screening.</p><p>In conclusion, most <italic>MLL</italic>wt cell lines show hypermethylation of <italic>BEX2, IGSF4 </italic>and <italic>TIMP3</italic>, while <italic>MLL</italic>mu cell lines are preferentially unmethylated.</p></sec><sec><title>Methylation of tumor suppressor genes in primary <italic>MLL</italic>mu and <italic>MLL</italic>wt AML cells</title><p>CpG island hypermethylation occurs more often in cell lines than in primary tumor cells [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. Controversial opinions exist on the question whether or not cell lines, including leukemia cell lines, show the same methylation profiles as the analogous primary cells [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B15">15</xref>]. To investigate the possible concordance of TSG methylation in cell lines and primary cells, we tested samples from <italic>MLL</italic>mu and <italic>MLL</italic>wt AML patients for TSG methylation. MS-MLPA assay detected low numbers of methylated TSG (mean 0.5/24 +/- 1.0 TSG) in primary AML cells, which is in accordance with earlier findings applying the same technique [<xref ref-type="bibr" rid="B16">16</xref>]. MSP has been shown to be a suitable and more sensitive technique for primary AML samples than MS-MLPA [<xref ref-type="bibr" rid="B17">17</xref>].</p><p>Therefore, we performed MSP after bisulfite conversion of DNA and detected methylated and unmethylated TSG promoter sequences using primers specific for <italic>BEX2, IGSF4, RARB </italic>and <italic>TIMP3</italic>, the most informative genes in our system (Fig. <xref ref-type="fig" rid="F3">3</xref>). For <italic>BEX2</italic>, <italic>IGSF4 </italic>and <italic>TIMP3</italic>, MSP indicated a trend towards an association between promoter methylation and <italic>MLL</italic>wt status (see Fig. <xref ref-type="fig" rid="F3">3B</xref> and Additional file <xref ref-type="supplementary-material" rid="S3">3</xref>). This correlation could not be observed for <italic>RARB</italic>, rendering this gene less interesting for our study. Bisulfite sequencing of the <italic>IGSF4 </italic>promoter region confirmed MSP results: <italic>MLL</italic>wt AML patients (#9, #14 and #15) and <italic>MLL</italic>wt cell line U-937 harbored clones with CpG methylation adjacent to the transcriptional start site of <italic>IGSF4</italic>, unlike <italic>MLL</italic>mu patient #23 and cell line THP-1 (see Fig. <xref ref-type="fig" rid="F4">4</xref>, Additional file <xref ref-type="supplementary-material" rid="S3">3</xref>).</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>TSG methylation in primary AML samples</bold>. Methylation status was assessed by MSP for <italic>BEX2</italic>, <italic>IGSF4</italic>, <italic>TIMP3 </italic>and <italic>RARB </italic>in a panel of <italic>MLL</italic>wt and <italic>MLL</italic>mu AML patients. A) Representative results for <italic>BEX2 </italic>MSP are shown. Patients #1 - #17 carry <italic>MLL</italic>wt, patients #18 - #40 harbor <italic>MLL </italic>rearrangements (see Additional file <xref ref-type="supplementary-material" rid="S3">3</xref>). B) Summary of methylation data obtained by MSP in patients. Lower percentages of <italic>MLL</italic>mu patients than <italic>MLL</italic>wt patients show promoter hypermethylation of <italic>BEX2, IGSF4 </italic>and <italic>TIMP3 </italic>(see also Additional file <xref ref-type="supplementary-material" rid="S3">3</xref>). C) Note that methylation of two out of three TSG (<italic>BEX2, IGSF4</italic>, <italic>TIMP3</italic>) is more frequent in <italic>MLL</italic>wt patients than in <italic>MLL</italic>mu patients.</p></caption><graphic xlink:href="1476-4598-8-86-3"/></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>Bisulfite sequencing of the <italic>IGSF4 </italic>promoter region</bold>. The <italic>IGSF4 </italic>promoter region (559 bp, 52 CpG sites) was sequenced after bisulfite conversion of DNA in two cell lines and selected AML patients. CpGs are represented as open dots (unmethylated) or filled dots (methylated). In <italic>MLL</italic>wt AML patients and in the <italic>MLL</italic>wt cell line U-937 clones with CpG methylation next to the transcriptional start site (TSS) were detected whereas no methylation was detectable in the <italic>MLL</italic>mu patient analyzed and in the <italic>MLL</italic>mu cell line THP-1. Note that CpG sites analyzed by the MS-MLPA probe (green) and MSP primers (red) are not identical.</p></caption><graphic xlink:href="1476-4598-8-86-4"/></fig><p>Using methylation of at least two out of the three relevant genes (<italic>BEX2, IGSF4 </italic>and <italic>TIMP3</italic>) as classifier for the <italic>MLL </italic>mutational status, the true positive identification rate (sensitivity) for <italic>MLL</italic>mu samples was 73%, with a specificity of 58%, supporting the conclusion that methylation of <italic>BEX2, IGSF4 </italic>and <italic>TIMP3 </italic>is more frequent in <italic>MLL</italic>wt than in <italic>MLL</italic>mu patients (Fig. <xref ref-type="fig" rid="F3">3C</xref>). Testing a larger cohort of patients will be necessary to confirm a statistically significant positive correlation between <italic>MLL </italic>mutational status and TSG methylation.</p></sec><sec><title>Inverse correlation of TSG methylation and expression</title><p>Hypermethylation of CpG islands in the promoter regions of TSG generally leads to the silencing of the respective genes [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. To test whether <italic>BEX2</italic>, <italic>IGSF4</italic>, <italic>RARB </italic>and <italic>TIMP3 </italic>were epigenetically regulated, we analyzed mRNA expression of these genes in cell lines by quantitative real-time PCR. Figure <xref ref-type="fig" rid="F5">5</xref> shows that three of the four genes analyzed (<italic>BEX2</italic>, <italic>IGSF4 </italic>and <italic>TIMP3</italic>) demonstrated an inverse correlation between TSG promoter methylation and gene expression consistent with epigenetic gene regulation. Predictive value for true methylation of these genes was 0.93, and accuracy 0.94. In contrast, <italic>RARB </italic>remained silent in most cell lines, independent of methylation status (Fig. <xref ref-type="fig" rid="F5">5</xref>). A similar result has been described for <italic>RARA</italic>: primary AML cells show low <italic>RARA2 </italic>expression although the promoter is not methylated confirming that regulation of gene transcription is a multi-factor process, not solely reliant on promoter methylation/demethylation [<xref ref-type="bibr" rid="B20">20</xref>]. Thus, (i) <italic>MLL</italic>mu AML cell lines express higher levels <italic>of BEX2, IGSF4 </italic>and <italic>TIMP3 </italic>than <italic>MLL</italic>wt cell lines, and (ii) these three TSG appear to be regulated by epigenetic mechanisms.</p><fig position="float" id="F5"><label>Figure 5</label><caption><p><bold>Inverse correlation between TSG methylation and expression</bold>. Hypomethylation (yellow) parallels RNA expression (red) of <italic>BEX2, IGSF4 </italic>and <italic>TIMP3 </italic>in <italic>MLL</italic>mu AML. <italic>MLL</italic>wt AML cell lines show hypermethylation (light green) and transcriptional silencing (green) of these. In contrast, <italic>RARB </italic>expression is low (green) even in cell lines that carry the unmethylated promoter (yellow). Excluding <italic>RARB</italic>, TSG hypermethylation inversely correlated with gene transcription in 94% of the cases. TSG methylation status is shown as determined by MS-MLPA (see Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). Gene expression was assessed in triplicates by quantitative real-time PCR (RT-PCR) analysis. For <italic>BEX2, IGSF4 </italic>and <italic>TIMP3</italic>, cell line IMS-M1 was applied as calibrator; for <italic>RARB</italic>, expression levels in cell line 697 were set as 1. Cell lines that reached relative expression levels &#x02265; 0.05 were considered positive (red).</p></caption><graphic xlink:href="1476-4598-8-86-5"/></fig><p><italic>RARB </italic>was excluded from further studies, as we neither observed an inverse correlation between <italic>RARB </italic>promoter methylation and gene expression in cell lines nor did we see a positive correlation between <italic>MLL</italic>mu and <italic>RARB </italic>hypomethylation in primary AML cells.</p><p>According to our findings, TSG hypomethylation and mRNA expression are characteristic features of <italic>MLL</italic>mu AML cells. This is in apparent conflict with the notion that MLL fusion proteins act as strong oncogenes, a view that is supported by the fact that <italic>MLL</italic>mu confers a dismal prognosis in AML. We hypothesize that <italic>BEX2, IGSF4 </italic>and <italic>TIMP3 </italic>are sentinel <italic>MLL </italic>fusion gene targets, their function being overridden by the strong oncogene <italic>MLL</italic>mu. A better understanding of how MLL fusion proteins impede TSG promoter methylation might help to illuminate a novel epigenetic role for <italic>MLL</italic>mu in leukemic cells.</p></sec><sec><title>DNA demethylation and histone acetylation induce expression of TSG</title><p>To verify epigenetic regulation of <italic>BEX2, IGSF4 </italic>and <italic>TIMP3</italic>, we applied the DNA-demethylating agent 5-Aza-2'-deoxycytidine (Aza) and the HDAC inhibitor trichostatin A (TSA). Our previous results had shown that these agents induced expression of <italic>BEX2 </italic>in <italic>MLL</italic>wt AML cell lines [<xref ref-type="bibr" rid="B5">5</xref>]. We show here that Aza and TSA also triggered mRNA expression of <italic>IGSF4 </italic>and <italic>TIMP3 </italic>(Table <xref ref-type="table" rid="T1">1</xref>). To confirm activity of TSA, histone H4K12 acetylation, a modification associated with active transcription, was analyzed (see Additional file <xref ref-type="supplementary-material" rid="S4">4</xref>). These results confirmed that epigenetic mechanisms are responsible for TSG silencing in <italic>MLL</italic>wt cell lines and suggest that TSG hypomethylation in <italic>MLL</italic>mu cell lines might be caused by alterations of epigenetic <italic>MLL </italic>functions as result of the various translocations.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Effects of Aza and TSA on TSG expression in <italic>MLL</italic>wt AML cell lines. </p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>cell line</bold></td><td align="center"><bold>treatment</bold></td><td align="center" colspan="3"><bold>TSG</bold></td></tr><tr><td></td><td></td><td colspan="3"><hr></hr></td></tr><tr><td></td><td></td><td align="center"><bold><italic>BEX2</italic></bold></td><td align="center"><bold><italic>IGSF4</italic></bold></td><td align="center"><bold><italic>TIMP3</italic></bold></td></tr></thead><tbody><tr><td align="center">AML-193</td><td align="center">TSA</td><td align="center">-</td><td align="center">-</td><td align="center"><bold>+</bold></td></tr><tr><td></td><td align="center">Aza</td><td align="center"><bold>++</bold></td><td align="center"><bold>++</bold></td><td align="center"><bold>+++</bold></td></tr><tr><td></td><td align="center">Aza + TSA</td><td align="center"><bold>++</bold></td><td align="center"><bold>++</bold></td><td align="center"><bold>+++</bold></td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="center">SKM-1</td><td align="center">TSA</td><td align="center"><bold>(+)</bold></td><td align="center"><bold>+</bold></td><td align="center"><bold>+</bold></td></tr><tr><td></td><td align="center">Aza</td><td align="center">-</td><td align="center"><bold>(+)</bold></td><td align="center"><bold>+</bold></td></tr><tr><td></td><td align="center">Aza + TSA</td><td align="center"><bold>+</bold></td><td align="center"><bold>+</bold></td><td align="center"><bold>++</bold></td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="center">U-937</td><td align="center">TSA</td><td align="center">-</td><td align="center"><bold>+</bold></td><td align="center"><bold>++</bold></td></tr><tr><td></td><td align="center">Aza</td><td align="center">-</td><td align="center"><bold>+++</bold></td><td align="center"><bold>+++</bold></td></tr><tr><td></td><td align="center">Aza + TSA</td><td align="center">-</td><td align="center"><bold>+++</bold></td><td align="center"><bold>+++</bold></td></tr></tbody></table><table-wrap-foot><p>Induction of TSG expression by Aza (5 &#x003bc;M, 4 d) and TSA (2 &#x003bc;M, 1 d) when compared to untreated control cells: - &#x0003c; 2-fold, + &#x02265; 2-fold; ++ &#x02265; 10-fold, +++ &#x02265; 100-fold gene expression. Expression levels were determined by quantitative real-time PCR. Note that cell line SKM-1 shows hypomethylation and expression of <italic>IGSF4 </italic>and <italic>TIMP3 </italic>(Fig. 5). Experiments were performed at least twice. Brackets: effect variable.</p></table-wrap-foot></table-wrap></sec><sec><title><italic>Bex2 </italic>transcription depends on expression of <italic>MLL-ENL</italic></title><p>To verify whether MLL fusion proteins were responsible for altered expression of TSG, we applied a mouse bone marrow cell line system that expresses <italic>MLL-ENL </italic>fused to the ligand-binding domain of the estrogen receptor. Removal of 4-hydroxytamoxifen (4-OHT) from the medium tethers MLL-ENL to a heat shock protein complex, thereby blocking the activation of the fusion protein [<xref ref-type="bibr" rid="B21">21</xref>]. Withdrawal of 4-OHT led to a marked decrease of <italic>Bex2 </italic>expression in this mouse cell system confirming that MLL fusion proteins serve to upregulate this gene (Fig. <xref ref-type="fig" rid="F6">6</xref>).</p><fig position="float" id="F6"><label>Figure 6</label><caption><p><bold>MLL fusion proteins regulate <italic>Bex2 </italic>expression</bold>. In presence of 4-OHT (100 nM) <italic>MLL-ENL</italic>-ERtm mouse cell lines expressed <italic>MLL-ENL </italic>and <italic>Bex2</italic>. Withdrawal of 4-OHT for seven to nine days induced downregulation of <italic>MLL-ENL </italic>and suppression of <italic>Bex2 </italic>transcription. <italic>Bex2 </italic>expression levels with standard deviations were determined in two different <italic>MLL-ENL</italic>-ERtm cell line clones by quantitative real-time PCR analysis.</p></caption><graphic xlink:href="1476-4598-8-86-6"/></fig><p>These results suggest that expression of TSG in <italic>MLL</italic>mu cell lines is attributable to the presence of MLL fusion proteins, raising the question whether the MLL fusion proteins directly target TSG promoters by blocking DNA methylation processes, or whether these effects are secondary.</p><p>It is difficult to attribute a specific oncogenic function to any single region of <italic>MLL </italic>fusion genes. Characteristic of the complexity of the situation is that many <italic>MLL </italic>translocations are reciprocal, and that both fusion genes are transcribed and may function oncogenically. However, <italic>MLL-ENL </italic>alone was sufficient to induce <italic>Bex2 </italic>in the transgene system indicating that the reciprocal fusion product was not required for regulation of this TSG. Furthermore, we observed TSG hypomethylation in various <italic>MLL</italic>mu cell lines with a variety of fusion partners. Together, these observations suggested that the inhibitory effect of <italic>MLL </italic>fusion genes on TSG promoter methylation was mediated by the N-terminal part of MLL and not by the fusion partner.</p><p>Both, the N-terminal and the C-terminal part of <italic>MLL </italic>have been implicated in transcriptional and/or epigenetic regulation. Located 3', the Su(var)3-9, enhancer-of-zeste, trithorax (SET) domain confers histone H3K4 methyltransferase activity to the protein [<xref ref-type="bibr" rid="B22">22</xref>]. However, histone H3K4 methylation is a marker for epigenetic activation and it appears unlikely that the loss of an activating function should lead to expression of TSG. Located upstream of the <italic>MLL </italic>breakpoint cluster region and retained in <italic>MLL </italic>fusion genes is the CXXC DNA methyltransferase homology domain, which binds CpG rich regions particularly when these are unmethylated [<xref ref-type="bibr" rid="B23">23</xref>]. This domain is essential for target gene recognition and is required for transformation by MLL fusion proteins [<xref ref-type="bibr" rid="B24">24</xref>]. Therefore, the CXXC domain might direct MLL to transcribed genes or possibly protect CpG islands against methylation. The N-terminal part of MLL has also been reported to bind menin [<xref ref-type="bibr" rid="B25">25</xref>]. MLL and menin are required for cellular transformation and both proteins cooperatively regulate expression of the genes p27<sup>Kip1 </sup>and p18<sup>Ink4c </sup>[<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B26">26</xref>].</p><p>Thus, regulation of TSG expression and alterations of epigenetic functions of MLL fusion proteins are feasible consequences of <italic>MLL </italic>translocations, but whether the TSG hypomethylation in <italic>MLL</italic>mu cell lines described by us is the direct effect of MLL fusion proteins or whether the hypomethylation is rather an indirect consequence, remains to be resolved. For two reasons we favor the latter explanation: <italic>MLL</italic>mu ALL cell lines do not show the TSG methylation profile that is typical for <italic>MLL</italic>mu AML suggesting that additional, tissue-specific factors play a role in this context. Furthermore, ChIP-DNA mircroarrays did not identify <italic>TIMP3 </italic>as target of wild-type <italic>MLL</italic>, the other two genes not being tested [<xref ref-type="bibr" rid="B27">27</xref>]. Future studies will have to provide evidence whether the MLL fusion proteins show altered DNA binding specificities than the wild-type protein allowing access to the promoters of the named TSG.</p></sec></sec><sec><title>Conclusion</title><p>We describe the conspicuous expression of TSG <italic>BEX2, IGSF4 </italic>and <italic>TIMP3 </italic>in <italic>MLLmu </italic>AML cells. In <italic>MLLwt </italic>cell lines these genes are silenced by promoter methylation. Transcription could be reactivated by treatment with demethylating agents and HDAC inhibitors. In <italic>MLLmu </italic>AML cell lines, constitutive expression of <italic>BEX2, IGSF4 </italic>and <italic>TIMP3 </italic>was accompanied by promoter hypomethylation. Ectopic expression of <italic>MLL-ENL </italic>drove upregulation of <italic>Bex2 </italic>in a tamoxifen-inducible mouse model indicating that the <italic>MLL </italic>fusion genes were responsible for upregulation of TSG mRNA. Taken together, our results suggest that hypomethylation of TSG characteristic of <italic>MLL</italic>mu AML cells may be the consequence of <italic>MLL </italic>gene alterations, including elements responsible for epigenetic regulation.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Human cell lines</title><p>The continuous cell lines were either taken from the stock of the cell bank (DSMZ - German Collection of Microorganisms and Cell Cultures) or were generously provided by the original investigators. Detailed references and cultivation protocols have been described previously [<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref>]. The following cell lines were tested for TSG methylation: (i) B-cell precursor (BCP) ALL-derived cell lines expressing <italic>MLL</italic>wt: 380, 697, MHH-CALL-2, MHH-CALL-3, MHH-CALL-4, NALM-6, SUP-B15; (ii) BCP ALL-derived cell lines with <italic>MLL</italic>mu: KOCL-33 t(11;19), KOCL-45 t(4;11), KOCL-58 t(4;11), KOPB-26 t(9;11), KOPN-8 t(11;19), RS4;11 t(4;11), SEM t(4;11); (iii) AML-derived cell lines with <italic>MLL</italic>wt: AML-193 (M5), MML-1 (M1), MUTZ-3 (M4), OCI-AML5 (M4), SKM-1 (M5), U-937 (M5), YNH-1 (M1); (iv) AML-derived cell lines with <italic>MLL</italic>mu: IMS-M1 (M5, t(9;11)), ML-2 (M4, t(6;11)), MOLM-13 (M5, t(9;11)), MONO-MAC-6 (M5, t(9;11)), MV4;11 (M5, t(4;11)), NOMO-1 (M5, t(9;11)), THP-1 (M5, t(9;11)).</p></sec><sec><title>Human tissue samples</title><p>After informed consent was given, bone marrow or peripheral blood specimens were obtained during routine clinical assessment of 40 AML patients. The collection of patient samples for analysis of genetic changes was approved by the local ethics committee. DNA extraction was performed from unselected cells from bone marrow or peripheral blood. The <italic>MLL</italic>wt/mu status of primary samples was assessed with long-distance PCR analysis, as described previously [<xref ref-type="bibr" rid="B30">30</xref>].</p></sec><sec><title>Methylation-specific multiplex ligation-dependent probe amplification assay</title><p>The MS-MLPA assay (ME001B; MRC-Holland, Amsterdam, Netherlands) simultaneously detects copy number changes and CpG methylation of the promoter regions of 24 different TSG. This semi-quantitative technique is based on digestion of DNA with the methylation-sensitive restriction enzyme <italic>Hha</italic>I (Fermentas, St. Leon-Rot, Germany) and a subsequent multiplex PCR followed by fragment analysis via capillary electrophoresis [<xref ref-type="bibr" rid="B31">31</xref>]. MS-MLPA data were analysed using a Microsoft Excel spreadsheet designed specifically for the ME001B assay. Levels of methylation were calculated by comparing the relative peak area of the <italic>HhaI </italic>digested ligation product with the corresponding ligation product from the undigested sample. Peak areas were normalised relative to neighbouring control ligation products prior to comparison as recommended by MRC-Holland. The spreadsheet for the analysis of the ME001B kit is freely available for download and use on the National Genetics Reference Laboratory website at <ext-link ext-link-type="uri" xlink:href="http://www.ngrl.org.uk/Manchester/mlpapubs.html"/>. For assessment of <italic>BEX2 </italic>promoter methylation, <italic>Hha</italic>I-digested and undigested DNA was used as template for subsequent quantitative real-time PCR using SYBR GREEN PCR Master Mix (Applied Biosystems, Foster City, CA, USA) in a 7500 Applied Biosystems real-time PCR system. The sequence flanked by primer pair A lacked <italic>Hha</italic>I sites, and was used as endogenous control. Sequence amplified by primer pair B contained two <italic>Hha</italic>I sites. The percentage of non-cleaved and thus methylated template in comparison to the undigested sample was calculated using the &#x00394;&#x00394;Ct-method. <italic>BEX2 </italic>A forward: 5'-GGT TGG TGA GAA GGA GGG TG-3'; <italic>BEX2 </italic>A reverse: 5'-GAG ACA CGA GTG ACG ACT GCA-3'; <italic>BEX2 </italic>B forward: 5'-TGG AGA GGA CGG AGA TGA GTG-3'; <italic>BEX2 </italic>B reverse: 5'-CAC CCT CCT TCT CAC CAA CC-3'. Methylation was scored positive when the calculated methylation percentage was &#x02265; 10%.</p></sec><sec><title>Methylation-specific polymerase chain reaction (MSP)</title><p>Bisulfite conversion of DNA was performed as described by the supplier (Active Motif, Rixensart, Belgium). For detecting TSG promoter methylation, we performed nested PCR with first round primers amplifying converted DNA independently of the methylation status (bisulfite-specific PCR), while second round primers for M- and U-PCR specifically recognized the methylated or unmethylated versions of the promoter. PCR products of the initial bisulfite-specific PCR were diluted 1:100 for subsequent M- and U-PCR. PCR conditions and primer sequences are listed in Additional file <xref ref-type="supplementary-material" rid="S5">5</xref>. Epitect PCR Control DNA (Qiagen, Hilden, Germany) was used as control for methylated and unmethylated templates.</p></sec><sec><title>Bisulfite sequencing</title><p>To confirm methylation status of the <italic>IGSF4 </italic>promoter, DNA of cell lines and AML patients was bisulfite converted according to the manufacturer's instructions (Active Motif). Subsequently, amplification of the <italic>IGSF4 </italic>promoter region (559 bp) was performed using primers <italic>IGSF4 </italic>BSP fwd and <italic>IGSF4 </italic>BSP rev, specifically binding bisulfite converted DNA (for primer sequence and PCR conditions see Additional file <xref ref-type="supplementary-material" rid="S5">5</xref>). Resulting <italic>IGSF4 </italic>fragments were purified, cloned into pGEM-T Easy vector (Promega, Madison, WI, USA) and sequenced. Sequences were evaluated using BiQ Analyzer <ext-link ext-link-type="uri" xlink:href="http://biq-analyzer.bioinf.mpi-sb.mpg.de"/> and had to conform to at least 90% bisulfite conversion rate. In addition, identical clones were excluded from the analysis.</p></sec><sec><title>Expression of tumor suppressor genes</title><p>Quantitative PCR was performed on a 7500 Applied Biosystems (Darmstadt, Germany) real-time PCR system using the manufacturer's protocol. RNA was prepared using the Trizol reagent (Invitrogen, Karlsruhe, Germany). For mRNA quantification, reverse transcription was performed using the SuperScript II reverse transcriptase kit (Invitrogen). TaqMan probes (Applied Biosystems) were used to quantify human <italic>BEX2 </italic>(Hs 00218464m1), <italic>IGSF4 </italic>(Hs 00204937m1), <italic>RARB </italic>(Hs 00233407m1) and <italic>TIMP3 </italic>(Hs 00927216m1) expression levels with <italic>TBP </italic>as endogenous control. Expression of mouse <italic>Bex2 </italic>was assessed using the SYBR GREEN PCR Master Mix (Applied Biosystems) with <italic>Tbp </italic>as internal control. <italic>Bex2 </italic>forward: 5'-GCG AGC GGG ACA GAT TGA C-3'; <italic>Bex2 </italic>reverse: 5'-TCC ATT TCT CCT GGG CCT ATC-3'. <italic>Tbp </italic>forward: 5'-ACC AGA ACA ACA GCC TTC CAC-3'; <italic>Tbp </italic>reverse: 5'-TGC CGT AAG GCA TCA TTG GAC-3'. Relative expression levels were calculated using the &#x00394;&#x00394;Ct-method.</p></sec><sec><title>Induction of <italic>MLL-ENL</italic></title><p>Mouse bone marrow cell lines <italic>MLL-ENL</italic>-ERtm 1 and 3 were maintained in RPMI 1640 medium supplemented with 10% FBS (Sigma, Taufkirchen, Germany), IL-3 (5 ng/ml), GM-CSF (5 ng/ml), IL-6 (5 ng/ml), SCF (50 ng/ml) and 4-OHT (100 nM). Murine cytokines were obtained from Richter-Helm (BioLogics, Hamburg, Germany) and 4-OHT was purchased from Sigma. 4-OHT releases MLL-ENL from a heat-shock protein complex thereby activating the fusion protein [<xref ref-type="bibr" rid="B21">21</xref>]. Note that MLL-ENL is essentially required for the continuous proliferation of this cell line.</p></sec><sec><title>Treatment with demethylating agents and inhibitors of histone deacetylases</title><p>Aza (Sigma) was used to verify the effect of methylation on expression of TSG. The HDAC inhibitor TSA (Sigma) was applied for testing the role of histone acetylation for TSG expression. Cells were seeded at a cell density of 5 &#x000d7; 10<sup>5 </sup>cells/ml, Aza was added at a final concentration of 5 &#x003bc;M. Control cells were treated with 0.05% DMSO. After 2 d, half of the medium was replenished with medium with/without Aza (5 &#x003bc;M). TSA (2 &#x003bc;M final concentration) was added for the last 24 h of cultivation. After 4 d, cells were harvested to prepare RNA and protein.</p></sec><sec><title>Histone purification and Western blot analysis</title><p>Histones were purified according to the protocol of the supplier (Active Motif). Then, 3.3 &#x003bc;g or 10 &#x003bc;g protein were separated by electrophoresis (15% SDS gels) to detect histones and acetylated histones, respectively. Anti acetyl histone H4K12 antiserum was obtained from Biomol/Upstate (Hamburg, Germany), anti histone H4 monoclonal Ab was purchased from Abcam (Cambridge, United Kingdom). Specific bands on nitrocellulose membranes were visualized with the biotin/streptavidin-horseradish peroxidase system (Amersham, Freiburg, Germany) in combination with the "Renaissance Western Blot Chemoluminescence Reagent" protocol (DuPont, Bad Homburg, Germany).</p></sec></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>SR designed parts of the study and performed MS-MLPA, MSP analysis, sequencing of bisulfite-converted DNA and co-wrote the manuscript, WGD established MLPA, CM performed <italic>MLL</italic>wt and <italic>MLL</italic>mu analysis for primary AML samples, RM provided patient samples and gave good advice, MS performed knock-down experiments, RS provided MLL-ENL-ERtm mouse cell lines and gave good advice, AW established the spreadsheets for the evaluation of MS-MLPA experiments, HGD provided cell lines and critically read the manuscript, HQ designed the study and wrote the manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>Methylation status of 24 TSG in 28 acute leukemia cell lines according to MS-MLPA</bold>. Shown is the promoter methylation status of TSG. Green: methylation &#x02265; 10%; yellow: methylation &#x0003c; 10%. TSG are arranged from left to right according to gene locus. For TSG <italic>CDKN2A </italic>and <italic>CDKN2B</italic>, ploidy status is indicated by numbers. Data shown are from one experiment per cell line. Reproducibility of MS-MLPA results was confirmed by up to four repetitions of analyses with selected cell lines.</p></caption><media xlink:href="1476-4598-8-86-S1.PDF" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p><bold>MSP analyses of <italic>BEX2</italic>, <italic>IGSF4 </italic>and <italic>TIMP3 </italic>in AML cell lines</bold>. Methylation status of <italic>BEX2</italic>, <italic>IGSF4 </italic>and <italic>TIMP3 </italic>were determined in <italic>MLL</italic>wt and <italic>MLL</italic>mu AML cell lines by MSP to control methylation status as determined by MS-MLPA. Results for M- and U-PCR are shown as well as the methylation status according to MS-MLPA. Performance of MS-MLPA as a classification system for methylated or unmethylated TSG was evaluated using a confusion matrix. Overall, the results of the techniques were in good concordance with an accuracy of 0.83. In detail, accuracy was 0.86 for <italic>BEX2</italic>, 0.93 for <italic>IGSF4 </italic>and 0.71 for <italic>TIMP3</italic>.</p></caption><media xlink:href="1476-4598-8-86-S2.JPEG" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S3"><caption><title>Additional file 3</title><p><bold>Methylation analyses in primary AML samples</bold>. Results of promoter methylation analysis according to MSP of <italic>BEX2, IGSF4, RARB </italic>and <italic>TIMP3 </italic>are shown for <italic>MLL</italic>mu and <italic>MLL</italic>wt AML patients</p></caption><media xlink:href="1476-4598-8-86-S3.DOC" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S4"><caption><title>Additional file 4</title><p><bold>Activating histone modifications induced by TSA</bold>. TSA effected acetylation of histone H4K12, as assessed by Western blot analysis. Aza treatment was not alone sufficient to induce histone H4K12 acetylation. <italic>MLL</italic>wt cell lines AML-193, SKM-1 and U-937 were treated with TSA (2 &#x003bc;M, 1 d), Aza (5 &#x003bc;M, 4 d) or a combination of both reagents.</p></caption><media xlink:href="1476-4598-8-86-S4.PDF" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S5"><caption><title>Additional file 5</title><p><bold>Primers for methylation-specific PCR</bold>. Primers and reaction conditions for BSP and MSP are listed.</p></caption><media xlink:href="1476-4598-8-86-S5.DOC" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>Acknowledgements: We thank Rod AF MacLeod for critically reading the manuscript. This study was in part supported by a grant from the Deutsche Krebshilfe (107819) to RM.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>SA</given-names></name><name><surname>Staunton</surname><given-names>JE</given-names></name><name><surname>Silverman</surname><given-names>LB</given-names></name><name><surname>Pieters</surname><given-names>R</given-names></name><name><surname>den Boer</surname><given-names>ML</given-names></name><name><surname>Minden</surname><given-names>MD</given-names></name><name><surname>Sallan</surname><given-names>SE</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Korsmeyer</surname><given-names>SJ</given-names></name></person-group><article-title>MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia</article-title><source>Nat Genet</source><year>2002</year><volume>30</volume><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">11731795</pub-id><pub-id pub-id-type="doi">10.1038/ng765</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quentmeier</surname><given-names>H</given-names></name><name><surname>Dirks</surname><given-names>WG</given-names></name><name><surname>MacLeod</surname><given-names>RAF</given-names></name><name><surname>Reinhardt</surname><given-names>J</given-names></name><name><surname>Zaborski</surname><given-names>M</given-names></name><name><surname>Drexler</surname><given-names>HG</given-names></name></person-group><article-title>Expression of HOX genes in acute leukemia cell lines with and without MLL translocations</article-title><source>Leukemia Lymphoma</source><year>2004</year><volume>45</volume><fpage>567</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">15160920</pub-id><pub-id pub-id-type="doi">10.1080/10428190310001609942</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quentmeier</surname><given-names>H</given-names></name><name><surname>Tonelli</surname><given-names>R</given-names></name><name><surname>Geffers</surname><given-names>R</given-names></name><name><surname>Pession</surname><given-names>A</given-names></name><name><surname>Uphoff</surname><given-names>CC</given-names></name><name><surname>Drexler</surname><given-names>HG</given-names></name></person-group><article-title>Expression of BEX1 in acute myeloid leukemia with MLL rearrangements</article-title><source>Leukemia</source><year>2005</year><volume>19</volume><fpage>1488</fpage><lpage>1489</lpage><pub-id pub-id-type="pmid">15920485</pub-id><pub-id pub-id-type="doi">10.1038/sj.leu.2403820</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>QS</given-names></name><name><surname>Xia</surname><given-names>F</given-names></name><name><surname>Gu</surname><given-names>SH</given-names></name><name><surname>Yuan</surname><given-names>HL</given-names></name><name><surname>Chen</surname><given-names>JZ</given-names></name><name><surname>Yang</surname><given-names>QS</given-names></name><name><surname>Ying</surname><given-names>K</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Mao</surname><given-names>YM</given-names></name></person-group><article-title>Cloning and expression pattern of a spermatogenesis-related gene, BEX1, mapped to chromosome Xq22</article-title><source>Biochem Genet</source><year>2002</year><volume>40</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">11989783</pub-id><pub-id pub-id-type="doi">10.1023/A:1014565320998</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>C</given-names></name><name><surname>Drexler</surname><given-names>HG</given-names></name><name><surname>Reinhardt</surname><given-names>J</given-names></name><name><surname>Zaborski</surname><given-names>M</given-names></name><name><surname>Quentmeier</surname><given-names>H</given-names></name></person-group><article-title>Epigenetic regulation of brain expressed X-linked-2, a marker for acute myeloid leukemia with mixed lineage leukemia rearrangements</article-title><source>Leukemia</source><year>2007</year><volume>21</volume><fpage>374</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">17251904</pub-id><pub-id pub-id-type="doi">10.1038/sj.leu.2404493</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Foltz</surname><given-names>G</given-names></name><name><surname>Ryu</surname><given-names>GY</given-names></name><name><surname>Yoon</surname><given-names>JG</given-names></name><name><surname>Nelson</surname><given-names>T</given-names></name><name><surname>Fahey</surname><given-names>J</given-names></name><name><surname>Frakes</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Field</surname><given-names>L</given-names></name><name><surname>Zander</surname><given-names>K</given-names></name><name><surname>Sibenaller</surname><given-names>Z</given-names></name><name><surname>Ryken</surname><given-names>TC</given-names></name><name><surname>Vibhakar</surname><given-names>R</given-names></name><name><surname>Hood</surname><given-names>L</given-names></name><name><surname>Madan</surname><given-names>A</given-names></name></person-group><article-title>Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>6665</fpage><lpage>6674</lpage><pub-id pub-id-type="pmid">16818640</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-4453</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Esteller</surname><given-names>M</given-names></name></person-group><article-title>Epigenetics in cancer</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>1148</fpage><lpage>1159</lpage><pub-id pub-id-type="pmid">18337604</pub-id><pub-id pub-id-type="doi">10.1056/NEJMra072067</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Costello</surname><given-names>JF</given-names></name><name><surname>Fr&#x000fc;hwald</surname><given-names>MC</given-names></name><name><surname>Smiraglia</surname><given-names>DJ</given-names></name><name><surname>Rush</surname><given-names>LJ</given-names></name><name><surname>Robertson</surname><given-names>GP</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Wright</surname><given-names>FA</given-names></name><name><surname>Feramisco</surname><given-names>JD</given-names></name><name><surname>Peltom&#x000e4;ki</surname><given-names>P</given-names></name><name><surname>Lang</surname><given-names>JC</given-names></name><name><surname>Schuller</surname><given-names>DE</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Bloomfield</surname><given-names>CD</given-names></name><name><surname>Caligiuri</surname><given-names>MA</given-names></name><name><surname>Yates</surname><given-names>A</given-names></name><name><surname>Nishikawa</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>HJS</given-names></name><name><surname>Petrelli</surname><given-names>NJ</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>O'Dorisio</surname><given-names>MS</given-names></name><name><surname>Held</surname><given-names>WA</given-names></name><name><surname>Cavenee</surname><given-names>WK</given-names></name><name><surname>Plass</surname><given-names>C</given-names></name></person-group><article-title>Aberrant CpG-island methylation has non-random and tumour-type-specific patterns</article-title><source>Nat Genet</source><year>2000</year><volume>25</volume><fpage>132</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">10835619</pub-id><pub-id pub-id-type="doi">10.1038/72785</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Esteller</surname><given-names>M</given-names></name><name><surname>Corn</surname><given-names>PG</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name><name><surname>Herman</surname><given-names>JG</given-names></name></person-group><article-title>A gene hypermethylation profile of human cancer</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>3225</fpage><lpage>3229</lpage><pub-id pub-id-type="pmid">11309270</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Esteller</surname><given-names>M</given-names></name></person-group><article-title>Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg</article-title><source>Clin Immunol</source><year>2003</year><volume>109</volume><fpage>80</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">14585279</pub-id><pub-id pub-id-type="doi">10.1016/S1521-6616(03)00208-0</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rahmatpanah</surname><given-names>FB</given-names></name><name><surname>Carstens</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Sjahutera</surname><given-names>O</given-names></name><name><surname>Taylor</surname><given-names>KH</given-names></name><name><surname>Duff</surname><given-names>D</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Davis</surname><given-names>JW</given-names></name><name><surname>Hooshmand</surname><given-names>SI</given-names></name><name><surname>Chitma-Matsiga</surname><given-names>R</given-names></name><name><surname>Caldwell</surname><given-names>CW</given-names></name></person-group><article-title>Differential DNA methylation patterns of small B-cell lymphoma subclasses with different clinical behavior</article-title><source>Leukemia</source><year>2006</year><volume>10</volume><fpage>1855</fpage><lpage>1862</lpage><pub-id pub-id-type="pmid">16900213</pub-id><pub-id pub-id-type="doi">10.1038/sj.leu.2404345</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Duff</surname><given-names>DJ</given-names></name><name><surname>Rahmatpanah</surname><given-names>F</given-names></name><name><surname>Chitima-Matsiga</surname><given-names>R</given-names></name><name><surname>Al-Kuhlani</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>KH</given-names></name><name><surname>Sjahputera</surname><given-names>O</given-names></name><name><surname>Andresi</surname><given-names>M</given-names></name><name><surname>Wooldridge</surname><given-names>JE</given-names></name><name><surname>Caldwell</surname><given-names>CW</given-names></name></person-group><article-title>Discovery of novel epigenetic markers in non-Hodgkin's lymphoma</article-title><source>Carcinogenesis</source><year>2007</year><volume>28</volume><fpage>60</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">16774933</pub-id><pub-id pub-id-type="doi">10.1093/carcin/bgl092</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smiraglia</surname><given-names>DJ</given-names></name><name><surname>Rush</surname><given-names>LJ</given-names></name><name><surname>Fr&#x000fc;hwald</surname><given-names>MC</given-names></name><name><surname>Dai</surname><given-names>Z</given-names></name><name><surname>Held</surname><given-names>WA</given-names></name><name><surname>Costello</surname><given-names>JF</given-names></name><name><surname>Lang</surname><given-names>JC</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Wright</surname><given-names>FA</given-names></name><name><surname>Caligiuri</surname><given-names>MA</given-names></name><name><surname>Plass</surname><given-names>C</given-names></name></person-group><article-title>Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies</article-title><source>Human Molecular Genetics</source><year>2001</year><volume>10</volume><fpage>1413</fpage><lpage>1419</lpage><pub-id pub-id-type="pmid">11440994</pub-id><pub-id pub-id-type="doi">10.1093/hmg/10.13.1413</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ueki</surname><given-names>T</given-names></name><name><surname>Walter</surname><given-names>KM</given-names></name><name><surname>Skinner</surname><given-names>H</given-names></name><name><surname>Jaffee</surname><given-names>E</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Goggins</surname><given-names>M</given-names></name></person-group><article-title>Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><fpage>2114</fpage><lpage>2117</lpage><pub-id pub-id-type="pmid">11960385</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1205275</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paz</surname><given-names>MF</given-names></name><name><surname>Fraga</surname><given-names>MF</given-names></name><name><surname>Avila</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Pollan</surname><given-names>M</given-names></name><name><surname>Herman</surname><given-names>JG</given-names></name><name><surname>Esteller</surname><given-names>M</given-names></name></person-group><article-title>A systematic profile of DNA methylation in human cancer cell lines</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>1114</fpage><lpage>1121</lpage><pub-id pub-id-type="pmid">12615730</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hess</surname><given-names>CJ</given-names></name><name><surname>Errami</surname><given-names>A</given-names></name><name><surname>Berkhof</surname><given-names>J</given-names></name><name><surname>Denkers</surname><given-names>F</given-names></name><name><surname>Ossenkoppele</surname><given-names>GJ</given-names></name><name><surname>Nygren</surname><given-names>AO</given-names></name><name><surname>Schuurhuis</surname><given-names>GJ</given-names></name><name><surname>Waisfisz</surname><given-names>Q</given-names></name></person-group><article-title>Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia</article-title><source>Leukemia Lymphoma</source><year>2008</year><volume>49</volume><fpage>1132</fpage><lpage>1141</lpage><pub-id pub-id-type="pmid">18569637</pub-id><pub-id pub-id-type="doi">10.1080/10428190802035990</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ekmekci</surname><given-names>CG</given-names></name><name><surname>Gutierrez</surname><given-names>MI</given-names></name><name><surname>Siraj</surname><given-names>AK</given-names></name><name><surname>Ozbek</surname><given-names>U</given-names></name><name><surname>Bhatia</surname><given-names>K</given-names></name></person-group><article-title>Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia</article-title><source>Am J Hematol</source><year>2004</year><volume>77</volume><fpage>233</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">15495254</pub-id><pub-id pub-id-type="doi">10.1002/ajh.20186</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>SH</given-names></name><name><surname>Bird</surname><given-names>AP</given-names></name></person-group><article-title>CpG islands and genes</article-title><source>Curr Opin Genet Dev</source><year>1995</year><volume>5</volume><fpage>309</fpage><lpage>314</lpage><pub-id pub-id-type="pmid">7549424</pub-id><pub-id pub-id-type="doi">10.1016/0959-437X(95)80044-1</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Esteller</surname><given-names>M</given-names></name></person-group><article-title>CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><fpage>5427</fpage><lpage>5440</lpage><pub-id pub-id-type="pmid">12154405</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1205600</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glasow</surname><given-names>A</given-names></name><name><surname>Barrett</surname><given-names>A</given-names></name><name><surname>Petrie</surname><given-names>K</given-names></name><name><surname>Guptka</surname><given-names>R</given-names></name><name><surname>Boix-Chornet</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>DC</given-names></name><name><surname>Grimwade</surname><given-names>D</given-names></name><name><surname>Gallagher</surname><given-names>R</given-names></name><name><surname>von Lindern</surname><given-names>M</given-names></name><name><surname>Waxman</surname><given-names>S</given-names></name><name><surname>Enver</surname><given-names>T</given-names></name><name><surname>Hildebrandt</surname><given-names>G</given-names></name><name><surname>Zelent</surname><given-names>A</given-names></name></person-group><article-title>DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia</article-title><source>Blood</source><year>2008</year><volume>111</volume><fpage>2374</fpage><lpage>2377</lpage><pub-id pub-id-type="pmid">17993618</pub-id><pub-id pub-id-type="doi">10.1182/blood-2007-05-088344</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zeisig</surname><given-names>BB</given-names></name><name><surname>Milne</surname><given-names>T</given-names></name><name><surname>Garcia-Cuellar</surname><given-names>MP</given-names></name><name><surname>Schreiner</surname><given-names>S</given-names></name><name><surname>Martin</surname><given-names>ME</given-names></name><name><surname>Fuchs</surname><given-names>U</given-names></name><name><surname>Borkhardt</surname><given-names>A</given-names></name><name><surname>Chanda</surname><given-names>SK</given-names></name><name><surname>Walker</surname><given-names>J</given-names></name><name><surname>Soden</surname><given-names>R</given-names></name><name><surname>Hess</surname><given-names>JL</given-names></name><name><surname>Slany</surname><given-names>RK</given-names></name></person-group><article-title>Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization</article-title><source>Mol Cell Biol</source><year>2004</year><volume>24</volume><fpage>617</fpage><lpage>628</lpage><pub-id pub-id-type="pmid">14701735</pub-id><pub-id pub-id-type="doi">10.1128/MCB.24.2.617-628.2004</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Milne</surname><given-names>TA</given-names></name><name><surname>Briggs</surname><given-names>SD</given-names></name><name><surname>Brock</surname><given-names>HW</given-names></name><name><surname>Martin</surname><given-names>ME</given-names></name><name><surname>Gibbs</surname><given-names>D</given-names></name><name><surname>Allis</surname><given-names>CD</given-names></name><name><surname>Hess</surname><given-names>JL</given-names></name></person-group><article-title>MLL targets SET domain methyltransferase activity to Hox gene promoters</article-title><source>Mol Cell</source><year>2002</year><volume>10</volume><fpage>1107</fpage><lpage>1117</lpage><pub-id pub-id-type="pmid">12453418</pub-id><pub-id pub-id-type="doi">10.1016/S1097-2765(02)00741-4</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Birke</surname><given-names>M</given-names></name><name><surname>Schreiner</surname><given-names>S</given-names></name><name><surname>Garcia-Cuellar</surname><given-names>MP</given-names></name><name><surname>Mahr</surname><given-names>K</given-names></name><name><surname>Titgemeyer</surname><given-names>F</given-names></name><name><surname>Slany</surname><given-names>RK</given-names></name></person-group><article-title>The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation</article-title><source>Nucleic Acids Research</source><year>2002</year><volume>30</volume><fpage>958</fpage><lpage>965</lpage><pub-id pub-id-type="pmid">11842107</pub-id><pub-id pub-id-type="doi">10.1093/nar/30.4.958</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ayton</surname><given-names>PM</given-names></name><name><surname>Chen</surname><given-names>EH</given-names></name><name><surname>Cleary</surname><given-names>ML</given-names></name></person-group><article-title>Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein</article-title><source>Mol Cell Biol</source><year>2004</year><volume>24</volume><fpage>10470</fpage><lpage>10478</lpage><pub-id pub-id-type="pmid">15542854</pub-id><pub-id pub-id-type="doi">10.1128/MCB.24.23.10470-10478.2004</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caslini</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>El-Osta</surname><given-names>M</given-names></name><name><surname>Milne</surname><given-names>TA</given-names></name><name><surname>Slany</surname><given-names>R</given-names></name><name><surname>Hess</surname><given-names>JL</given-names></name></person-group><article-title>Interaction of MLL amino terminal sequences with menin is required for transformation</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>7275</fpage><lpage>7283</lpage><pub-id pub-id-type="pmid">17671196</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-2369</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Milne</surname><given-names>TA</given-names></name><name><surname>Hughes</surname><given-names>CM</given-names></name><name><surname>Lloyd</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Rozenblatt-Rosen</surname><given-names>O</given-names></name><name><surname>Dou</surname><given-names>Y</given-names></name><name><surname>Schnepp</surname><given-names>RW</given-names></name><name><surname>Krankel</surname><given-names>C</given-names></name><name><surname>Livolsi</surname><given-names>VA</given-names></name><name><surname>Gibbs</surname><given-names>D</given-names></name><name><surname>Hua</surname><given-names>X</given-names></name><name><surname>Roeder</surname><given-names>RG</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Hess</surname><given-names>JL</given-names></name></person-group><article-title>Menin and MLL cooperatively regulated expression of cyclin-dependent kinase inhibitors</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>749</fpage><lpage>754</lpage><pub-id pub-id-type="pmid">15640349</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0408836102</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guenther</surname><given-names>MG</given-names></name><name><surname>Jenner</surname><given-names>RG</given-names></name><name><surname>Chavalier</surname><given-names>B</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name><name><surname>Canaani</surname><given-names>E</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name></person-group><article-title>Global and Hox-specific roles for the MLL1 methyltransferase</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>8603</fpage><lpage>8608</lpage><pub-id pub-id-type="pmid">15941828</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0503072102</pub-id></citation></ref><ref id="B28"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Drexler</surname><given-names>HG</given-names></name></person-group><source>Guide to Leukemia-Lymphoma Cell Lines Braunschweig</source><year>2005</year></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drexler</surname><given-names>HG</given-names></name><name><surname>Quentmeier</surname><given-names>H</given-names></name><name><surname>MacLeod</surname><given-names>RAF</given-names></name></person-group><article-title>Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations</article-title><source>Leukemia</source><year>2004</year><volume>18</volume><fpage>227</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">14671638</pub-id><pub-id pub-id-type="doi">10.1038/sj.leu.2403236</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>C</given-names></name><name><surname>Schneider</surname><given-names>B</given-names></name><name><surname>Reichel</surname><given-names>M</given-names></name><name><surname>Angerm&#x000fc;ller</surname><given-names>S</given-names></name><name><surname>Strehl</surname><given-names>S</given-names></name><name><surname>Schnittger</surname><given-names>S</given-names></name><name><surname>Schoch</surname><given-names>C</given-names></name><name><surname>Jansen</surname><given-names>MW</given-names></name><name><surname>van Dongen</surname><given-names>JJ</given-names></name><name><surname>Pieters</surname><given-names>R</given-names></name></person-group><article-title>Diagnostic tool for the identification of MLL rearrangements including unknown partner genes</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>449</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">15626757</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0406994102</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nygren</surname><given-names>AO</given-names></name><name><surname>Ameziane</surname><given-names>N</given-names></name><name><surname>Duarte</surname><given-names>HM</given-names></name><name><surname>Vijzelaar</surname><given-names>RN</given-names></name><name><surname>Waisfisz</surname><given-names>O</given-names></name><name><surname>Hess</surname><given-names>CJ</given-names></name><name><surname>Schouten</surname><given-names>JP</given-names></name><name><surname>Errami</surname><given-names>A</given-names></name></person-group><article-title>Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences</article-title><source>Nucleic Acids Res</source><year>2005</year><volume>33</volume><fpage>e128</fpage><pub-id pub-id-type="pmid">16106041</pub-id><pub-id pub-id-type="doi">10.1093/nar/gni127</pub-id></citation></ref></ref-list></back></article> 